State of the art in topical wound-healing products

Plastic and Reconstructive Surgery

Volumn 127, Issue SUPPL. 1 S, 2011, Pages

  Fan, Kenneth ^a   Tang, Jennifer ^a   Escandon, Julia ^a   Kirsner, Robert S ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; SIGNAL PEPTIDE;

ARTICLE; ARTIFICIAL SKIN; BANDAGE; CHRONIC DISEASE; DRUG EFFECT; HUMAN; INJURY; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SKIN TRANSPLANTATION; TISSUE ENGINEERING; TOPICAL DRUG ADMINISTRATION; WOUND HEALING;

ADMINISTRATION, TOPICAL; ANTI-INFECTIVE AGENTS; BANDAGES; CHRONIC DISEASE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SKIN TRANSPLANTATION; SKIN, ARTIFICIAL; TISSUE ENGINEERING; WOUND HEALING; WOUNDS AND INJURIES;

EID: 78651302306     PISSN: 00321052     EISSN: None     Source Type: Journal    
DOI: 10.1097/PRS.0b013e3181fbe275     Document Type: Article

References (157)

1. Centers for Medicare & Medicaid Services. Guidance to surveyors for long term care facilities. Available at: http:// www.cms.hhs.gov. Accessed April 4, 2010
2. Lin P, Phillips TJ. Approach to diagnosis of a patient with a lower extremity ulcer. In: Falabella AF, Kirsner RS, eds. Wound Healing. Boca Raton, Fla: Taylor & Francis Group; 2005:69-81
3. Phillips T, Stanton B, Provan A, Lew R. A study of the impact of leg ulcers on quality of life: Financial, social, and psychologic implications. J Am Acad Dermatol. 1994;31:49-53
4. Mustoe TA, O'Shaughnessy K, Kloeters O. Chronic wound pathogenesis and current treatment strategies: A unifying hypothesis. Plast Reconstr Surg. 2006;117:35S-41S
5. Singer AJ, Clark RA. Cutaneous wound healing. N Engl J Med. 1999;341:738-746
6. Clark RA. Cutaneous tissue repair: Basic biologic considerations. I. J Am Acad Dermatol. 1985;13:701-725
7. Loots MA, Lamme EN, Zeegelaar J, Mekkes JR, Bos JD, Middelkoop E. Differences in cellular infiltrate and extracellular matrix of chronic diabetic and venous ulcers versus acute wounds. J Invest Dermatol. 1998;111:850-857
8. Wang XJ, Han G, Owens P, Siddiqui Y, Li AG. Role of TGF beta-mediated inflammation in cutaneous wound healing. J Investig Dermatol Symp Proc. 2006;11:112-117
9. Trengove NJ, Bielefeldt-Ohmann H, Stacey MC. Mitogenic activity and cytokine levels in non-healing and healing chronic leg ulcers. Wound Repair Regen. 2000;8:13-25
10. Wetzler C, Kampfer H, Stallmeyer B, Pfeilschifter J, Frank S. Large and sustained induction of chemokines during impaired wound healing in the genetically diabetic mouse: Prolonged persistence of neutrophils and macrophages during the late phase of repair. J Invest Dermatol. 2000;115:245-253
11. Trengove NJ, Stacey MC, MacAuley S, et al. Analysis of the acute and chronic wound environments: The role of proteases and their inhibitors. Wound Repair Regen. 1999;7:442-452
12. Yager DR, Nwomeh BC. The proteolytic environment of chronic wounds. Wound Repair Regen. 1999;7:433-441
13. Tarnuzzer RW, Schultz GS. Biochemical analysis of acute and chronic wound environments. Wound Repair Regen. 1996;4:321-325
14. Grinnell F, Ho CH, Wysocki A. Degradation of fibronectin and vitronectin in chronic wound fluid: Analysis by cell blotting, immunoblotting, and cell adhesion assays. J Invest Dermatol. 1992;98:410-416
15. Stadelmann WK, Digenis AG, Tobin GR. Physiology and healing dynamics of chronic cutaneous wounds. Am J Surg. 1998;176:26S-38S
16. Bowler PG. Wound pathophysiology, infection and therapeutic options. Ann Med. 2002;34:419-427
17. Hohn DC, MacKay RD, Halliday B, Hunt TK. Effect of O2 tension on microbicidal function of leukocytes in wounds and in vitro. Surg Forum 1976;27:18-20
18. Chang N, Goodson WH III, Gottrup F, Hunt TK. Direct measurement of wound and tissue oxygen tension in postoperative patients. Ann Surg. 1983;197:470-478
19. Granger DN. Role of xanthine oxidase and granulocytes in ischemia-reperfusion injury. Am J Physiol. 1988;255:H1269-H1275
20. Martin LK. Wound microbiology and the use of antibacterial agents. In: Falabella AF, Kirsner RS, eds. Wound Healing. Boca Raton, Fla: Taylor & Francis Group; 2005:83-101
21. Ovington L. The art and science of wound dressings in the twenty-first century. In: Falabella AF, Kirsner RS, eds. Wound Healing. Boca Raton, Fla: Taylor & Francis Group; 2005:1-7
22. Eriksson G, Eklund AE, Kallings LO. The clinical significance of bacterial growth in venous leg ulcers. Scand J Infect Dis. 1984;16:175-180
23. Hutchinson JJ, Lawrence JC. Wound infection under occlusive dressings. J Hosp Infect. 1991;17:83-94
24. Pruitt BA Jr. The diagnosis and treatment of infection in the burn patient. Burns Incl Therm Inj. 1984;11:79-91
25. Krizek TJ, Robson MC. Evolution of quantitative bacteriology in wound management. Am J Surg. 1975;130:579-584
26. Viljanto J. Disinfection of surgical wounds without inhibition of normal wound healing. Arch Surg. 1980;115:253-256
27. Hess CT, Kirsner RS. Orchestrating wound healing: Assessing and preparing the wound bed. Adv Skin Wound Care 2003;16:246-257; quiz 258-259
28. Elek SD. Experimental staphylococcal infections in the skin of man. Ann N Y Acad Sci. 1956;65:85-90
29. Nelson EA, Bradley MD. Dressings and topical agents for arterial leg ulcers. Cochrane Database Syst Rev. 2007;1: CD001836
30. Palfreyman SJ, Nelson EA, Lochiel R, Michaels JA. Dressings for healing venous leg ulcers. Cochrane Database Syst Rev. 2006;3:CD001103
31. Cuzzell J. Choosing a wound dressing. Geriatr Nurs. 1997; 18:260-265
32. Chaby G, Senet P, Vaneau M, et al. Dressings for acute and chronic wounds: A systematic review. Arch Dermatol. 2007; 143:1297-1304
33. Hanna JR, Giacopelli JA. A review of wound healing and wound dressing products. J Foot Ankle Surg. 1997;36:2-14; discussion 79
34. Hess CT. Wound Care . 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2005
35. Jones V, Grey JE, Harding KG. Wound dressings. BMJ. 2006; 332:777-780
36. Falanga V. Occlusive wound dressings: Why, when, which? Arch Dermatol. 1988;124:872-877
37. Heyneman A, Beele H, Vanderwee K, Defloor T. A systematic review of the use of hydrocolloids in the treatment of pressure ulcers. J Clin Nurs. 2008;17:1164-1173
38. Winter GD. Formation of the scab and the rate of epithelization of superficial wounds in the skin of the young domestic pig. Nature 1962;193:293-294
39. Hinman CD, Miabach H. Effect of air exposure and occlusion on experimental human skin wounds. Nature 1963; 200:377-378
40. Alper JC, Welch EA, Ginsberg M, Bogaars H, Maguire P. Moist wound healing under a vapor permeable membrane. J Am Acad Dermatol. 1983;8:347-353
41. Eaglstein WH, Mertz PM. New methods for assessing epidermal wound healing: The effects of triamcinolone acetonide and polyethelene film occlusion. J Invest Dermatol. 1978;71:382-384
42. Katz MH, Alvarez AF, Kirsner RS, Eaglstein WH, Falanga V. Human wound fluid from acute wounds stimulates fibroblast and endothelial cell growth. J Am Acad Dermatol. 1991; 25:1054-1058
43. Chen WY, Rogers AA, Lydon MJ. Characterization of biologic properties of wound fluid collected during early stages of wound healing. J Invest Dermatol. 1992;99:559-564
44. Alper JC, Tibbetts LL, Sarazen AA Jr. The in vitro response of fibroblasts to the fluid that accumulates under a vaporpermeable membrane. J Invest Dermatol. 1985;84:513-515
45. Eaglstein WH, Falanga V. Chronic wounds. Surg Clin North Am. 1997;77:689-700
46. Friedman SJ, Su WP. Management of leg ulcers with hydrocolloid occlusive dressing. Arch Dermatol. 1984;120:1329-1336
47. Barnett A, Berkowitz RL, Mills R, Vistnes LM. Comparison of synthetic adhesive moisture vapor permeable and fine mesh gauze dressings for split-thickness skin graft donor sites. Am J Surg. 1983;145:379-381
48. Nemeth AJ, Eaglstein WH, Taylor JR, Peerson LJ, Falanga V. Faster healing and less pain in skin biopsy sites treated with an occlusive dressing. Arch Dermatol. 1991;127:1679-1683
49. Eaglstein WH, Davis SC, Mehle AL, Mertz PM. Optimal use of an occlusive dressing to enhance healing: Effect of delayed application and early removal on wound healing. Arch Dermatol. 1988;124:392-395
50. Hutchinson JJ, McGuckin M. Occlusive dressings: A microbiologic and clinical review. Am J Infect Control 1990;18:257-268
51. Rivera AE, Spencer JM. Clinical aspects of full-thickness wound healing. Clin Dermatol. 2007;25:39-48
52. De Coninck A, Draye JP, Van Strubarq A, et al. Healing of full-thickness wounds in pigs: Effects of occlusive and nonocclusive dressings associated with a gel vehicle. J Dermatol Sci. 1996;13:202-211
53. Dyson M, Young S, Pendle CL, Webster DF, Lang SM. Comparison of the effects of moist and dry conditions on dermal repair. J Invest Dermatol. 1988;91:434-439
54. Bucalo B, Eaglstein WH, Falanga V. Inhibition of cell proliferation by chronic wound fluid. Wound Repair Regen. 1993; 1:181-186
55. Phillips TJ, al-Amoudi HO, Leverkus M, Park HY. Effect of chronic wound fluid on fibroblasts. J Wound Care 1998;7: 527-532
56. Kirshen C, Woo K, Ayello EA, Sibbald RG. Debridement: A vital component of wound bed preparation. Adv Skin Wound Care 2006;19:506-519
57. Kim YC, Shin JC, Park CI, Oh SH, Choi SM, Kim YS. Efficacy of hydrocolloid occlusive dressing technique in decubitus ulcer treatment: A comparative study. Yonsei Med J. 1996;37:181-185
58. Ohlsson P, Larsson K, Lindholm C, Moller M. A cost-effectiveness study of leg ulcer treatment in primary care: Comparison of saline-gauze and hydrocolloid treatment in a prospective, randomized study. Scand J Prim Health Care 1994;12:295-299
59. Phillips TJ, Palko MJ, Bhawan J. Histologic evaluation of chronic human wounds treated with hydrocolloid and nonhydrocolloid dressings. J Am Acad Dermatol. 1994;30:61-64
60. American Diabetes Association. Consensus Development Conference on Diabetic Foot Wound Care; April 7-8, 1999; Boston, Mass
61. Vermeulen H, Ubbink DT, Goossens A, de Vos R, Legemate DA. Systematic review of dressings and topical agents for surgical wounds healing by secondary intention. Br J Surg. 2005;92:665-672
62. Bradley M, Cullum N, Nelson EA, Petticrew M, Sheldon T, Torgerson D. Systematic reviews of wound care management: (2). dressings and topical agents used in the healing of chronic wounds. Health Technol Assess. 1999;3:1-35
63. Singh A, Halder S, Menon GR, et al. Meta-analysis of randomized controlled trials on hydrocolloid occlusive dressing versus conventional gauze dressing in the healing of chronic wounds. Asian J Surg. 2004;27:326-332
64. Reddy M, Gill SS, Kalkar SR, Wu W, Anderson PJ, Rochon PA. Treatment of pressure ulcers: A systematic review. JAMA. 2008;300:2647-2662
65. Edwards J, Stapley S. Debridement of diabetic foot ulcers. Cochrane Database Syst Rev. 2010;1:CD003556
66. Bouza C, Munoz A, Amate JM. Efficacy of modern dressings in the treatment of leg ulcers: A systematic review. Wound Repair Regen. 2005;13:218-229
67. Palfreyman S, Nelson EA, Michaels JA. Dressings for venous leg ulcers: Systematic review and meta-analysis. BMJ. 2007; 335:244
68. Vermeulen H, van Hattem JM, Storm-Versloot MN, Ubbink DT. Topical silver for treating infected wounds. Cochrane Database Syst Rev. 2007;1:CD005486
69. Sisco M, Mustoe TA. Animal models of ischemic wound healing: Toward an approximation of human chronic cutaneous ulcers in rabbit and rat. Methods Mol Med. 2003;78:55-65
70. Whitney J, Phillips L, Aslam R, et al. Guidelines for the treatment of pressure ulcers. Wound Repair Regen. 2006;14:663-679
71. Steed DL, Attinger C, Colaizzi T, et al. Guidelines for the treatment of diabetic ulcers. Wound Repair Regen. 2006;14: 680-692
72. O'Donnell TF Jr, Lau J. A systematic review of randomized controlled trials of wound dressings for chronic venous ulcer. J Vasc Surg. 2006;44:1118-1125
73. Hopf HW, Ueno C, Aslam R, et al. Guidelines for the treatment of arterial insufficiency ulcers. Wound Repair Regen. 2006;14:693-710
74. Robson MC, Cooper DM, Aslam R, et al. Guidelines for the treatment of venous ulcers. Wound Repair Regen. 2006;14: 649-662
75. Apelqvist J, Bakker K, van Houtum WH, Nabuurs-Franssen MH, Schaper NC. International consensus and practical guidelines on the management and the prevention of the diabetic foot: International Working Group on the Diabetic Foot. Diabetes Metab Res Rev. 2000;16(Suppl 1):S84-S92
76. Edwards JV, Bopp AF, Batiste S, et al. Inhibition of elastase by a synthetic cotton-bound serine protease inhibitor: In vitro kinetics and inhibitor release. Wound Repair Regen. 1999;7:106-118
77. Jorgensen B, Price P, Andersen KE, et al. The silver-releasing foam dressing, Contreet Foam, promotes faster healing of critically colonised venous leg ulcers: A randomised, controlled trial. Int Wound J. 2005;2:64-73
78. Purna SK, Babu M. Collagen based dressings: A review. Burns 2000;26:54-62
79. Cullen B, Watt PW, Lundqvist C, et al. The role of oxidised regenerated cellulose/collagen in chronic wound repair and its potential mechanism of action. Int J Biochem Cell Biol. 2002;34:1544-1556
80. Lobmann R, Zemlin C, Motzkau M, Reschke K, Lehnert H. Expression of matrix metalloproteinases and growth factors in diabetic foot wounds treated with a protease absorbent dressing. J Diabetes Complications 2006;20:329-335
81. Veves A, Sheehan P, Pham HT. A randomized, controlled trial of Promogran (a collagen/oxidized regenerated cellulose dressing) vs standard treatment in the management of diabetic foot ulcers. Arch Surg. 2002;137:822-827
82. Vin F, Teot L, Meaume S. The healing properties of Promogran in venous leg ulcers. J Wound Care 2002;11:335-341
83. Niezgoda JA, Van Gils CC, Frykberg RG, Hodde JP. Randomized clinical trial comparing OASIS Wound Matrix to Regranex Gel for diabetic ulcers. Adv Skin Wound Care 2005; 18:258-266
84. Mostow EN, Haraway GD, Dalsing M, Hodde JP, King D; OASIS Venus Ulcer Study Group. Effectiveness of an extracellular matrix graft (OASIS wound matrix) in the treatment of chronic leg ulcers: A randomized clinical trial. J Vasc Surg. 2005;41:837-843
85. Romanelli M, Dini V, Bertone MS. Randomized comparison of OASIS wound matrix versus moist wound dressing in the treatment of difficult-to-heal wounds of mixed arterial/ venous etiology. Adv Skin Wound Care 2010;23:34-38
86. Mustoe T. Understanding chronic wounds: A unifying hypothesis on their pathogenesis and implications for therapy. Am J Surg. 2004;187:65S-70S
87. McDonnell G, Russell AD. Antiseptics and disinfectants: Activity, action, and resistance. Clin Microbiol Rev. 1999;12: 147-179
88. Drosou A, Falabella A, Kirsner RS. Antiseptic on wounds: Area of controversy. Wounds 2003;15:149-166
89. -56 Federal Register 33644 at 33662
90. Howell JM, Stair TO, Howell AW, Mundt DJ, Falcone A, Peters SR. The effect of scrubbing and irrigation with normal saline, povidone iodine, and cefazolin on wound bacterial counts in a guinea pig model. Am J Emerg Med. 1993; 11:134-138
91. Lammers RL, Fourre M, Callaham ML, Boone T. Effect of povidone-iodine and saline soaking on bacterial counts in acute, traumatic, contaminated wounds. Ann Emerg Med. 1990;19:709-714
92. Kucan JO, Robson MC, Heggers JP, Ko F. Comparison of silver sulfadiazine, povidone-iodine and physiologic saline in the treatment of chronic pressure ulcers. J Am Geriatr Soc. 1981;29:232-235
93. Houang ET, Gilmore OJ, Reid C, Shaw EJ. Absence of bacterial resistance to povidone iodine. J Clin Pathol. 1976; 29:752-755
94. Landis SJ. Chronic wound infection and antimicrobial use. Adv Skin Wound Care 2008;21:531-42
95. Orsted H, Sibbald RG. Topical treatment of wound infection. In: Falabella AF, Kirsner RS, eds. Wound Healing. Boca Raton, Fla: Taylor & Francis Group; 2005:599-615
96. O'Meara S, Al-Kurdi D, Ologun Y, Ovington LG. Antibiotics and antiseptics for venous leg ulcers. Cochrane Database Syst Rev. 2010;1:CD003557
97. Hansson C. The effects of cadexomer iodine paste in the treatment of venous leg ulcers compared with hydrocolloid dressing and paraffin gauze dressing: Cadexomer iodine study group. Int J Dermatol. 1998;37:390-396
98. Lamme EN, Gustafsson TO, Middelkoop E. Cadexomeriodine ointment shows stimulation of epidermal regeneration in experimental full-thickness wounds. Arch Dermatol Res. 1998;290:18-24
99. Lau WY, Wong SH. Randomized, prospective trial of topical hydrogen peroxide in appendectomy wound infection: High risk factors. Am J Surg. 1981;142:393-397
100. Gruber RP, Vistnes L, Pardoe R. The effect of commonly used antiseptics on wound healing. Plast Reconstr Surg. 1975; 55:472-476
101. Smith RG. A critical discussion of the use of antiseptics in acute traumatic wounds. J Am Podiatr Med Assoc. 2005;95: 148-153
102. Klasen HJ. A historical review of the use of silver in the treatment of burns: II. renewed interest for silver. Burns 2000;26:131-138
103. Bader KF. Organ deposition of silver following silver nitrate therapy of burns. Plast Reconstr Surg. 1966;37:550-551
104. Storm-Versloot MN, Vos CG, Ubbink DT, Vermeulen H. Topical silver for preventing wound infection. Cochrane Database Syst Rev. 2010;3:CD006478
105. Wasiak J, Cleland H, Campbell F. Dressings for superficial and partial thickness burns. Cochrane Database Syst Rev. 2008; 4:CD002106
106. Hendry AT, Stewart IO. Silver-resistant Enterobacteriaceae from hospital patients. Can J Microbiol. 1979;25:915-921
107. Kramer SA. Effect of povidone-iodine on wound healing: A review. J Vasc Nurs. 1999;17:17-23
108. Moyer CA, Brentano L, Gravens DL, Margraf HW, Monafo WW Jr. Treatment of large human burns with 0.5 per cent silver nitrate solution. Arch Surg. 1965;90:812-867
109. Atiyeh BS, Costagliola M, Hayek SN, Dibo SA. Effect of silver on burn wound infection control and healing: Review of the literature. Burns 2007;33:139-148
110. Fox CL Jr. Silver sulfadiazine: A new topical therapy for Pseudomonas in burns. Therapy of Pseudomonas infection in burns. Arch Surg. 1968;96:184-188
111. Lowbury EJ, Babb JR, Bridges K, Jackson DM. Topical chemoprophylaxis with silver sulphadiazine and silver nitrate chlorhexidine creams: Emergence of sulphonamide-resistant Gram-negative bacilli. BMJ. 1976;1:493-496
112. Poon VK, Burd A. In vitro cytotoxity of silver: Implication for clinical wound care. Burns 2004;30:140-147
113. Stern HS. Silver sulphadiazine and the healing of partial thickness burns: A prospective clinical trial. Br J Plast Surg. 1989;42:581-585
114. O'Meara SM, Cullum NA, Majid M, Sheldon TA. Systematic review of antimicrobial agents used for chronic wounds. Br J Surg. 2001;88:4-21
115. Bergin SM, Wraight P. Silver based wound dressings and topical agents for treating diabetic foot ulcers. Cochrane Database Syst Rev. 2006;1:CD005082
116. Cohen S. Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new-born animal. J Biol Chem. 1962;237:1555-1562
117. Doughty D, Sparks-Defriese B. Wound-healing physiology. In: Bryant RA, Nix DP, eds. Acute&Chronic Wounds: Current Management Concepts. 3rd ed. St. Louis: Mosby/Elsevier; 2007:56-81
118. Higley HR, Ksander GA, Gerhardt CO, Falanga V. Extravasation of macromolecules and possible trapping of transforming growth factor-beta in venous ulceration. Br J Dermatol. 1995;132:79-85
119. Harding KG, Morris HL, Patel GK. Science, medicine and the future: Healing chronic wounds. BMJ. 2002;324:160-163
120. Hammacher A, Mellstrom K, Heldin CH, Westermark B. Isoform-specific induction of actin reorganization by platelet- derived growth factor suggests that the functionally active receptor is a dimer. EMBO J. 1989;8:2489-2495
121. Smiell JM, Wieman TJ, Steed DL, Perry BH, Sampson AR, Schwab BH. Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: A combined analysis of four randomized studies. Wound Repair Regen. 1999;7:335-346
122. U.S. Food and Drug Administration. FDA announces new labeling changes for Regranex: Product to carry boxed warning. Available at: http://www.fda.gov/ NewsEvents/ Newsroom/PressAnnouncements/2008/ucm116909.htm. Accessed March 18, 2010
123. Jarvis CI. Becaplermin (Regranex) for diabetic foot ulcers. Am Fam Physician 2008;78:255-256
124. Steed DL. Clinical evaluation of recombinant human platelet- derived growth factor for the treatment of lower extremity diabetic ulcers. Diabetic Ulcer Study Group. J Vasc Surg. 1995;21:71-78; discussion 79-81
125. Wieman TJ, Smiell JM, Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers: A phase III randomized placebo-controlled double-blind study. Diabetes Care 1998;21:822-827
126. Li W. Personal communication, 2008
127. Brown GL, Nanney LB, Griffen J, et al. Enhancement of wound healing by topical treatment with epidermal growth factor. N Engl J Med. 1989;321:76-79
128. Kaplan G, Walsh G, Guido LS, et al. Novel responses of human skin to intradermal recombinant granulocyte/macrophage- colony-stimulating factor: Langerhans cell recruitment, keratinocyte growth, and enhanced wound healing. J Exp Med. 1992;175:1717-1728
129. Janis JE, Kwon RK, Lalonde DH. A practical guide to wound healing. Plast Reconstr Surg. 2010;125:230e-244e
130. Limova M. Cultured skin substitutes. In: Falabella AF, Kirsner RS, eds. Wound Healing. Boca Raton, Fla: Taylor & Francis Group; 2005:545-559
131. Eisenbud D, Huang NF, Luke S, Silberklang M. Skin substitutes and wound healing: Current status and challenges. Wounds 2004;16:2-17
132. Falanga V, Margolis D, Alvarez O, et al. Rapid healing of venous ulcers and lack of clinical rejection with an allogeneic cultured human skin equivalent. Human Skin Equivalent Investigators Group. Arch Dermatol. 1998;134:293-300
133. Marston WA, Hanft J, Norwood P, Pollak R; Dermagraft Diabetic Foot Ulcer Study Group. The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers: Results of a prospective randomized trial. Diabetes Care 2003;26:1701-1705
134. Veves A, Falanga V, Armstrong DG, Sabolinski ML; Apligraf Diabetic Foot Ulcer Study. Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: A prospective randomized multicenter clinical trial. Diabetes Care 2001;24:290-295
135. Heimbach D, Luterman A, Burke J, et al. Artificial dermis for major burns: A multi-center randomized clinical trial. Ann Surg. 1988;208:313-320
136. Purdue GF, Hunt JL, Still JM Jr, et al. A multicenter clinical trial of a biosynthetic skin replacement, Dermagraft-TC, compared with cryopreserved human cadaver skin for temporary coverage of excised burn wounds. J Burn Care Rehabil. 1997;18:52-57
137. Hansbrough JF, Mozingo DW, Kealey GP, Davis M, Gidner A, Gentzkow GD. Clinical trials of a biosynthetic temporary skin replacement, Dermagraft-Transitional Covering, compared with cryopreserved human cadaver skin for temporary coverage of excised burn wounds. J Burn Care Rehabil. 1997;18:43-51
138. Phillips TJ. New skin for old: Developments in biological skin substitutes. Arch Dermatol. 1998;134:344-349
139. Wainwright DJ. Use of an acellular allograft dermal matrix (AlloDerm) in the management of full-thickness burns. Burns 1995;21:243-248
140. Burke JF, Yannas IV, Quinby WC Jr, Bondoc CC, Jung WK. Successful use of a physiologically acceptable artificial skin in the treatment of extensive burn injury. Ann Surg. 1981; 194:413-428
141. Stern R, McPherson M, Longaker MT. Histologic study of artificial skin used in the treatment of full-thickness thermal injury. J Burn Care Rehabil. 1990;11:7-13
142. Michaeli D, McPherson M. Immunologic study of artificial skin used in the treatment of thermal injuries. J Burn Care Rehabil. 1990;11:21-26
143. Jimenez PA, Jimenez SE. Tissue and cellular approaches to wound repair. Am J Surg. 2004;187:56S-64S
144. Eaglstein WH, Alvarez OM, Auletta M, et al. Acute excisional wounds treated with a tissue-engineered skin (Apligraf). Dermatol Surg. 1999;25:195-201
145. Wilkins LM, Watson SR, Prosky SJ, Meunier SF, Parenteau NL. Development of a bilayered living skin construct for clinical applications. Biotechnol Bioeng. 1994;43:747-756
146. Cooper ML, Hansbrough JF, Spielvogel RL, Cohen R, Bartel RL, Naughton G. In vivo optimization of a living dermal substitute employing cultured human fibroblasts on a biodegradable polyglycolic acid or polyglactin mesh. Biomaterials 1991;12:243-248
147. Herndon DN. Perspectives in the use of allograft. J Burn Care Rehabil. 1997;18:S6
148. Naughton G, Mansbridge J, Gentzkow G. A metabolically active human dermal replacement for the treatment of diabetic foot ulcers. Artif Organs 1997;21:1203-1210
149. Bello YM, Phillips TJ. Recent advances in wound healing. JAMA. 2000;283:716-718
150. Sabolinski ML, Alvarez O, Auletta M, Mulder G, Parenteau NL. Cultured skin as a 'smart material' for healing wounds: Experience in venous ulcers. Biomaterials 1996;17:311-320
151. Broughton G II, Janis JE, Attinger CE. Wound healing: An overview. Plast Reconstr Surg. 2006;117:1S-32S
152. Jones JE, Nelson EA. Skin grafting for venous leg ulcers. Cochrane Database Syst Rev. 2007;2:CD001737
153. Buinewicz B, Rosen B. Acellular cadaveric dermis (Allo- Derm): A new alternative for abdominal hernia repair. Ann Plast Surg. 2004;52:188-194
154. Spear SL, Parikh PM, Reisin E, Menon NG. Acellular dermis- assisted breast reconstruction. Aesthetic Plast Surg. 2008; 32:418-425
155. Gamboa-Bobadilla GM. Implant breast reconstruction using acellular dermal matrix. Ann Plast Surg. 2006;56:22-25
156. Ryan CM, Schoenfeld DA, Malloy M, Schulz JT III, Sheridan RL, Tompkins RG. Use of Integra artificial skin is associated with decreased length of stay for severely injured adult burn survivors. J Burn Care Rehabil. 2002;23:311-317
157. Moiemen NS, Staiano JJ, Ojeh NO, Thway Y, Frame JD. Reconstructive surgery with a dermal regeneration template: Clinical and histologic study. Plast Reconstr Surg. 2001; 108:93-103